Vaccine-focused biopharma Dynavax Technologies (DVAX) has announced a collaboration to develop a universal influenza (flu) vaccine with the Icahn School of Medicine at Mount Sinai.Mount Sinai’s work in this area is funded under a contract award from the National Institute of Allergy and Infectious Diseases (NIAID), as part of the Collaborative Influenza Vaccine Innovation Centers (CIVICs) program.The Mount Sinai CIVICs team will evaluate a novel approach they have developed called chimeric hemagglutinin (cHA) designed to protect against all strains of influenza in combination with Dynavax’s CpG 1018TM adjuvant.Adjuvants are added to a vaccine to boost the immune response to produce …read more
Source:: Yahoo Finance
